Similiar legislation died last year after getting House approval.

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

The pharmaceutical landscape sees movement beyond the courtroom as Biogen focuses on growth from new product launches rather than acquisitions to drive future revenues. Similarly, Bayer's ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. For the quarter ended December ...

Pharmaceutic, chemical company Monsanto was found liable by a Washington jury for $100 million on Tuesday, according to ...

The health data company, based in Bellevue, Washington, plans to collect leftover specimens from consenting patients who get routine health care at participating facilities, Stat reported. Also in the ...